MITIGATE-NeoBOMB1:一项评估68Ga-NeoBOMB1(胃泌素释放肽受体拮抗剂)在胃肠道间质瘤患者中安全性、药代动力学和初步显像的I/IIa期研究
这项I/IIa期临床试验在6例酪氨酸激酶抑制剂治疗的晚期胃肠道间质瘤(GIST)患者中评估了68Ga-NeoBOMB1的安全性、生物分布、剂量学和初步肿瘤靶向性。68Ga-NeoBOMB1(50 μg,174 ± 28 MBq)耐受良好,平均有效剂量为0.029 ± 0.06 mSv/MBq,胰腺剂量最高(0.274 ± 0.099 mSv/MBq);3例患者肿瘤病灶可见随时间增加的显著摄取(注射后2小时SUVmax 4.3-25.9)。
要点
- 68Ga-NeoBOMB1在GIST患者中耐受良好,安全性和药代动力学适合PET显像。
- 平均有效剂量0.029 ± 0.06 mSv/MBq,最高器官剂量为胰腺(0.274 ± 0.099 mSv/MBq)。
- 3例患者肿瘤病灶显示随时间增加的显著摄取,注射后2小时SUVmax为4.3-25.9。
核心结论
- 这项I/IIa期研究提供了68Ga-NeoBOMB1的安全性数据,该放射性药物是靶向GRPR表达肿瘤的有前景的显像剂。
- 安全性和药代动力学适合PET显像,吸收剂量估计与其他临床常规使用的68Ga标记放射性药物相当。
研究设计与样本
- I/IIa期临床试验(EudraCT 2016-002053-38),纳入6例组织学确诊的GIST患者,原发灶不可切除或转移,正在接受酪氨酸激酶抑制剂治疗。
- 68Ga-NeoBOMB1采用试剂盒法经许可的68Ge/68Ga发生器制备,按3 MBq/kg体重静脉注射。
- PET/CT包括注射后5、11、19分钟的动态显像以及1、2、3-4小时的静态显像用于剂量学计算,并采集静脉血和尿液进行药代动力学分析。
主要发现
- 68Ga-NeoBOMB1(50 μg)放射化学纯度>97%,患者接受174 ± 28 MBq,在4周随访期间所有患者耐受良好。
- 剂量学计算显示平均有效剂量为0.029 ± 0.06 mSv/MBq,最高器官剂量为胰腺(0.274 ± 0.099 mSv/MBq)。
- 平均血浆半衰期为27.3分钟,主要经肾脏清除(注射后4小时平均25.7% ± 5.4%的注入剂量)。
- 血浆代谢物分析显示高稳定性,代谢物仅在尿液中检测到。
- 3例患者肿瘤病灶可见显著摄取,SUVmax随时间增加(注射后2小时SUVmax为4.3-25.9)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Gastrin-releasing peptide receptors (GRPRs) are potential molecular imaging targets in a variety of tumors. Recently, a 68Ga-labeled antagonist to GRPRs, NeoBOMB1, was developed for PET. We report on the outcome of a phase I/IIa clinical trial (EudraCT 2016-002053-38) within the EU-FP7 project Closed-loop Molecular Environment for Minimally Invasive Treatment of Patients with Metastatic Gastrointestinal Stromal Tumors ('MITIGATE') (grant agreement no. 602306) in patients with oligometastatic gastrointestinal stromal tumors (GIST). Methods: The main objectives were evaluation of safety, biodistribution, dosimetry, and preliminary tumor targeting of 68Ga-NeoBOMB1 in patients with advanced tyrosine-kinase inhibitors-treated GIST using PET/CT. Six patients with histologically confirmed GIST and unresectable primary lesion or metastases undergoing an extended protocol for detailed pharmacokinetic analysis were included. 68Ga-NeoBOMB1 was prepared using a kit procedure with a licensed 68Ge/68Ga generator. 68Ga-NeoBOMB1 (3 MBq/kg of body weight) was injected intravenously, and safety parameters were assessed. PET/CT included dynamic imaging at 5, 11, and 19 min as well as static imaging at 1, 2, and 3-4 h after injection for dosimetry calculations. Venous blood samples and urine were collected for pharmacokinetic analysis. Tumor targeting was assessed on a per-lesion and per-patient basis. Results:68Ga-NeoBOMB1 (50 μg) was prepared with high radiochemical purity (yield > 97%). Patients received 174 ± 28 MBq of the radiotracer, which was well tolerated in all patients over a follow-up period of 4 wk. Dosimetry calculations revealed a mean effective dose of 0.029 ± 0.06 mSv/MBq, with the highest organ dose to the pancreas (0.274 ± 0.099 mSv/MBq). Mean plasma half-life was 27.3 min with primarily renal clearance (mean 25.7% ± 5.4% of injected dose 4 h after injection). Plasma metabolite analyses revealed high stability; metabolites were detected only in the urine. In 3 patients, a significant uptake with increasing maximum SUVs (SUVmax at 2 h after injection: 4.3-25.9) over time was found in tumor lesions. Conclusion: This phase I/IIa study provides safety data for 68Ga-NeoBOMB1, a promising radiopharmaceutical for targeting GRPR-expressing tumors. Safety profiles and pharmacokinetics are suitable for PET imaging, and absorbed dose estimates are comparable to those of other 68Ga-labeled radiopharmaceuticals used in clinical routine.
引用
- Gruber L, Jiménez-Franco LD, Decristoforo C, et al. MITIGATE-NeoBOMB1, a Phase I/IIa Study to Evaluate Safety, Pharmacokinetics, and Preliminary Imaging of 68Ga-NeoBOMB1, a Gastrin-Releasing Peptide Receptor Antagonist, in GIST Patients. J Nucl Med. 2020. PMID: 32332143. doi:10.2967/jnumed.119.238808
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。